1. HURP binding to the vinca domain of β-tubulin accounts for cancer drug resistance
- Author
-
Athira Saju, Po-Pang Chen, Tzu-Han Weng, Su-Yi Tsai, Akihiro Tanaka, Yu-Ting Tseng, Chih-Chia Chang, Chun-Hsiung Wang, Yuta Shimamoto, and Kuo-Chiang Hsia
- Subjects
Science - Abstract
Abstract Vinca alkaloids, a class of tubulin-binding agent, are widely used in treating cancer, yet the emerging resistance compromises their efficacy. Hepatoma up-regulated protein (HURP), a microtubule-associated protein displaying heightened expression across various cancer types, reduces cancer cells’ sensitivity to vinca-alkaloid drugs upon overexpression. However, the molecular basis behind this drug resistance remains unknown. Here we discover a tubulin-binding domain within HURP, and establish its role in regulating microtubule growth. Cryo-EM analysis reveals interactions between HURP’s tubulin-binding domain and the vinca domain on β-tubulin -- the site targeted by vinca alkaloid drugs. Importantly, HURP competes directly with vinorelbine, a vinca alkaloid-based chemotherapeutic agent, countering microtubule growth defects caused by vinorelbine both in vitro and in vivo. Our findings elucidate a mechanism driving drug resistance in HURP-overexpressing cancer cells and emphasize HURP tubulin-binding domain’s role in mitotic spindle assembly. This underscores its potential as a therapeutic target to improve cancer treatment.
- Published
- 2024
- Full Text
- View/download PDF